Skip to main content

Table 1 Patient characteristics (N = 63)

From: Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients

Variables N (%)
Age (year), median (range) 70.9 (52.7–93.0)
Race
 White 49 (77.8)
 Black 11 (17.5)
 Other 3 (4.8)
Gleason score at diagnosis
 6 3 (4.8)
 7 15 (23.8)
 8 10 (15.9)
 9 26 (41.3)
 10 4 (6.4)
 Unknown 5 (7.9)
ECOG performance status
 0 25 (39.7)
 1 28 (44.4)
 2 8 (12.7)
 3 1 (1.6)
 Unknown 1 (1.6)
Bone metastasis
 No 3 (4.8)
 Yes 60 (95.2)
Visceral metastasis  
 No 51 (81.0)
 Yes 12 (19.0)
Previous ARSi therapy
 No 34 (54.0)
 Yes 29 (46.0)
Previous chemotherapy
 No 38 (60.3)
 Yes 25 (39.7)
ARSi therapy after blood draw
 No 16 (25.4)
 Yes 47 (74.6)
Cytotoxic therapy after blood draw
 No 46 (73.0)
 Yes 17 (27.0)
Absolute neutrophil (B/L), median (range) 4.2 (1.0–15.4)
Absolute lymphocyte (B/L), median (range) 1.0 (0.3–10.4)
Platelet (B/L), median (range) 214 (73–513)
Neutrophil-to-lymphocyte ratio, median (range) 3.7 (0.3–20.6)
Platelet-to-lymphocyte ratio, median (range) 200 (12.9–1126.9)
Prostate-specific antigen (ng/ml), median (range) 8.8 (0.1–1169.0)
Hemoglobin (g/dL), median (range) 12.1 (7.4–14.6)
Alkaline phosphatase (IU/L), median (range) 86 (36–1709)
Albumin (g/dL), median (range) 4.1 (2.7–4.7)
Lactate dehydrogenase (IU/L), median (range)a 212 (149–560)
Vital status
 Alive 40 (63.5)
 Dead 23 (36.5)
  1. ECOG Eastern Cooperative Oncology Group; ARSi androgen receptor signaling inhibitor
  2. a: data were available from 24 patients